Anzeige
Meldung des Tages: Der nächste Lithium-Runner? EMP startet entscheidende Engineering-Phase

Mindmaze Therapeutics News

Aktie
WKN:  A3EFB5 ISIN:  CH1251125998 US-Symbol:  RLFTF Branche:  Biotechnologie Land:  Schweiz
0,451 CHF
+0,011 CHF
+2,50%
0,49926 € 13.03.26
Depot/Watchlist
Marktkapitalisierung *
30,60 Mio. €
Streubesitz
46,07%
KGV
-
Index-Zuordnung
-

Mindmaze Therapeutics News

12.03.26 - EQS
MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale
MindMaze Therapeutics Holding SA / Key word(s): Personnel MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale ...
03.03.26 - EQS
MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation
MindMaze Therapeutics Holding SA / Key word(s): Miscellaneous MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation 03-March-...
23.12.25 - EQS
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
Relief Therapeutics Holding SA / Key word(s): Miscellaneous MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-​Generation Therapeutics ...
15.12.25 - EQS
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics 15-Dec-...
25.11.25 - EQS
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated ...
14.11.25 - EQS
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Shareholders Approve Business Combination with NeuroX 14-Nov-2025 / 18:20 CET/CEST Release of ...
29.10.25 - EQS
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 29-Oct-2025 / 07:00 ...
24.10.25 - EQS
Relief Therapeutics Convenes Extraordinary General Meeting
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Convenes Extraordinary General Meeting 24-Oct-2025 / 06:59 CET/CEST Release of an ad hoc ...
08.10.25 - EQS
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business ...
14.08.25 - EQS
Relief Therapeutics Publishes 2025 Half-Year Report
Relief Therapeutics Holding SA / Key word(s): Half Year Results Relief Therapeutics Publishes 2025 Half-Year Report 14-Aug-2025 / 07:00 CET/CEST Release of an ad hoc ...
11.08.25 - EQS
Relief Therapeutics Advances Publication of 2025 Half-Year Report
Relief Therapeutics Holding SA / Key word(s): Half Year Results Relief Therapeutics Advances Publication of 2025 Half-Year Report 11.08.2025 / 07:00 CET/CEST
29.07.25 - EQS
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze 29-Jul-...
20.06.25 - EQS
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 20-Jun-2025 / 07:00 CET/CEST ...
12.06.25 - EQS
Relief Therapeutics Announces Results of Annual General Meeting
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Annual General Meeting 12.06.2025 / 11:00 CET/CEST
22.05.25 - EQS
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
Relief Therapeutics Holding SA / Key word(s): Research Update Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 22-May-2025 / 07:00 ...
15.05.25 - EQS
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Publishes 2025 Annual General Meeting Agenda 15.05.2025 / 07:00 CET/CEST
10.04.25 - EQS
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Holding SA / Key word(s): Annual Results Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update 10-Apr-2025 / 07:00 CET/CEST ...

Newssuche

Videos

newspaper
13.03.26 -4,81%
Technical Trading: Kurzfristig Gold Long
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »